Remove Government Remove Pharmaceuticals Remove Virus
article thumbnail

Issue 07 is Coming on Monday

Codon

Falling out of fashion with the rise of the modern pharmaceutical industry, it’s ready for a comeback driven not by mania, but rather by a mechanistic understanding of the molecules and bioactive compounds responsible for its efficacy. A History of Fermentation.

article thumbnail

Coronavirus vaccine: UK signs deals for 90 million virus vaccine doses

The Pharma Data

The UK government has signed deals for a further 90 million doses of coronavirus vaccine. The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. Inactivated whole virus vaccines: 60 million doses Valneva. Image copyright. Most of the vaccines require only two.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Keeping tabs on Covid-19: Iceni Diagnostics creates new virus detection device and the RDIF announce its vaccine is more than 95 per cent efficient

The Pharma Data

This week, another pharma company revealed a new technology device that can detect if a patient is infectious or not, while the Russian government published results of its Sputnik V vaccine, claiming it is more than 95 per cent efficient 42 days after the first dose. Read on to for the full insight.

Virus 52
article thumbnail

Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

The Pharma Data

Regeneron Pharmaceuticals, Inc. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 FDA, which is reviewing an Emergency Use Authorization submission for the REGN-COV2 low dose in adults with mild-to-moderate COVID-19 who are at high risk for poor outcomes.

Virus 40
article thumbnail

BioCryst Provides Update on Galidesivir Program

The Pharma Data

22, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19.

article thumbnail

Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19

The Pharma Data

REGN-COV2 could provide a much-needed treatment option for people already experiencing symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic. Reliable, high-quality testing is essential to help healthcare systems overcome this pandemic.

article thumbnail

Tonix Pharmaceuticals Enrolls First Participant in the PRECISION Study, an Observational Study to Facilitate Development of Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

The Pharma Data

15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. President and Chief Executive Officer of Tonix Pharmaceuticals.

Vaccine 40